Skip to content

JBIO JBIO Investing Cash Flow

Investing Cash Flow at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
-$431.9M-674%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$21.55M-47.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$137.82M-1,000%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$34.98M+136%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$25.51M
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$32.41M-11.9%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's investing cash flow?
JBIO (JBIO) reported investing cash flow of -$8.47M in Q1 2026.
How has JBIO's investing cash flow changed year-over-year?
JBIO's investing cash flow decreased by 165.9% year-over-year, from $12.85M to -$8.47M.
What is the long-term trend for JBIO's investing cash flow?
Over 2 years (2021 to 2025), JBIO's investing cash flow has grown at a 47.6% compound annual growth rate (CAGR), from -$113.43M to -$247.01M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.